VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > VMS+ tech. and its unique contributions to advancing cardiac

<< Previous

Bullboard Posts

Next >>

Post by jopatcloon Jun 21, 2024 7:33am

79 Views

Post# 36099499

VMS+ tech. and its unique contributions to advancing cardiac

In this article, we explore the transformative potential of Artificial Intelligence (AI) in clinical trials, highlighting its current challenges in daily clinical practice and showcasing how AI is revolutionizing the field of cardiology. We will delve into the specific advantages AI offers in improving efficiency, accuracy, and outcomes in clinical trials, with a special focus on Ventripoint's VMS+ technology and its unique contributions to advancing cardiac research.